ELLICOTT CITY, MD, UNITED STATES, March 19, 2026 /EINPresswire.com/ — The Hereditary Neuropathy Foundation (HNF) will host ...
An FDA complete response letter for idebenone in LHON indicates unresolved NDA deficiencies and necessitates additional data ...
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and ...
The 15-20 National Hospital and GenSight Biologics announce the first patient treated in the French Named Patient Early Access Programme for GS010/Lumevoq: Paris, France Monday, M ...
The first group of patients in the GS010 AAC program were treated at the 15-20 National Hospital in Paris on March 19. The REVISE dose-ranging study is proceeding according to the planned ...
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA ...
The Muscular Dystrophy Association (MDA) concluded its 2026 MDA Clinical & Scientific Conference yesterday, convening over 2,400 attendees from 40 countries to help shape the future of neuromuscular ...
CV autonomic dysfunction is prevalent in patients with wild-type transthyretin-mediated amyloid cardiomyopathy, despite being underreported.
Discusses Progress and Strategy in Transforming ATTR Amyloidosis Care and Expanding TTR Franchise March 24, 2026 ...
Why Vertex, Bayer, Alnylam, and Sanofi are among the most innovative companies developing new treatments and medicines.
Detailed price information for Intellia Thera CS (NTLA-Q) from The Globe and Mail including charting and trades.
The MDA's annual conference highlighted recent breakthroughs and the outlook for future care in the neuromuscular disease community.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results